Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Corvus Pharmaceuticals  (Stock symbol: CRVS )

863 Mitten Road, Suite 102
Burlingame, CA 94010
USA
650-900-4520
Website Company Summary Management Team
Management

CEO: Richard A. Miller (11/30/2014)
General Management: William Ben Jones (2015) ; Joseph J. Buggy (11/30/2014)
Finance: Leiv Lea (12/31/2014)
Technology: Erik Verner (1/31/2015)
Board

Outside board: (May no longer be on the board) Peter Thompson (OrbiMed Private Equity Partner) Peter Moldt (Novo Ventures Partner) Terry Gould (Adams Street Partners Partner)
Company

Business description: Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology. Corvus is developing new drugs and antibodies that block crucial immune checkpoints, and reprogram immune T cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it was found to be safe and demonstrated favorable pharmacologic properties. It will enter cancer clinical trials soon. The management team of Corvus includes inventors and scientists who played key roles in the development of Rituxan, Imbruvica and Zelboraf.
Capital

Rounds: 2
Recent Fundings: Sep 2015   Jul 2015
Capital raised: 108.0M
Last Round: 75.0M
Ownership: Public   Ipo Filing
Stock Symbol: CRVS
VCs include: Adams Street Partners OrbiMed BlackRock ;  Novo Ventures ;  Jennison Associates ;  Rock Springs Capital Management Cormorant Asset Management Fidelity Management and Research Company ;  Cowen Private Investments ;  Sphera Funds Management ;  venBIO Select
Corporate investors: Roche Venture Fund

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2016
Sector: Biotech
Headcount: 51-75 as of Feb 2019
Rounds: 2
Recent Fundings: Sep 2015   Jul 2015
Capital Raised: 108.0M
Last Round: 75.0M
Ownership: Public   Ipo Filing
Stock Symbol: CRVS